Acuity Pharmaceuticals Inc. and Intradigm Corp. agreed to combine their work in the field of RNA interference to develop topical and other formulations of Acuity's Cand5, a compound aimed at treating ...
HINGHAM, Mass., April 19, 2006 (PRIMEZONE) -- Pathogenics, Inc. (Other OTC:PTGN) today announced that it has licensed to Acuity Pharmaceuticals, Inc. the exclusive worldwide rights to N-Chlorotaurine, ...
Consistent earnings growth is perhaps the most important thing for a company to aim for. Almost everyone, right from the top brass to research analysts, is captivated by this metric. But why is this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results